Y-mAbs Therapeutics, Inc.
YMABDelisted Sep 16, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001722964
Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Y-mAbs Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Y-mAbs Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hamill Laura | Director | 0 | Sep 19, 2025 | 0 |
| Gill David N | Director | 0 | Sep 18, 2025 | 0 |
| Healy James | Director | 0Indirect | Sep 18, 2025 | 0 |
| Pfreundschuh Peter P. | EVP, CFO and Treasurer | 0 | Sep 18, 2025 | 0 |
| LaRocca John | SVP, General Counsel & Secry | 0 | Sep 18, 2025 | 0 |
| Tyagi Ashu | Director | 0 | Sep 18, 2025 | 0 |
| Wedell-Wedellsborg Johan | Director, 10% Owner | 0Indirect | Sep 18, 2025 | 0 |
| WG Biotech ApS | Director, 10% Owner | 0 | Sep 18, 2025 | 0 |
| Gad Thomas | CHIEF BUSINESS OFFICER | 0Indirect | Sep 18, 2025 | 0 |
| Wilms Joris | SVP & CHIEF OPERATING OFFICER | 0 | Sep 18, 2025 | 0 |
| Rossi Michael J | PRESIDENT & CEO | 0 | Sep 18, 2025 | 0 |
| Gentilcore Douglas J | SVP, Danyelza Bus. Unit Head | – | Sep 18, 2025 | 0 |
| Lund-Hansen Torben | SVP & CHIEF TECHNICAL OFFICER | 35,600 | Aug 30, 2024 | 0 |
| Tagliaferri Mary | Director | 8,155 | Jun 13, 2024 | 0 |
| Ber Gerard | Director | 1,608 | Jun 11, 2024 | 0 |
| Kruse Bo | EVP, CFO, SECRY & TREAS. | 210,877 | May 31, 2024 | 0 |
| Rajah Vignesh | SVP & CHIEF MEDICAL OFFICER | 33,889 | Mar 7, 2024 | 0 |
| Smith Susan Laura | SVP & CHIEF COMMERCIAL OFFICER | 33,918 | Mar 7, 2024 | 0 |
| Lisby Steen | SVP & CHIEF SCIENTIFIC OFFICER | 35,600 | Jan 22, 2024 | 0 |
| Moller-San Pedro Claus Juan | Director and CEO | – | Dec 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2023 (view filing) | Dec 11 | 1 day | WG Biotech ApSDirector | PPurchase | +6.46K | $6.85 | +$44.2K | +0.1%4.56M after | Duplicate filing |
| Dec 15, 2023 (view filing) | Dec 13-15 | 2 days | Gad ThomasChief Business Officer | SSale | −150.0K | $6.67 | −$1.00M | −36.1%265.0K after | 3 lots |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Smith Susan LauraSVP & CHIEF COMMERCIAL OFFICER | SSale | −1.68K | $16.55 | −$27.8K | −4.7%33.9K after | |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −3.90K | $16.44 | −$64.1K | −2.4%158.7K after | |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Rajah VigneshSVP & CHIEF MEDICAL OFFICER | SSale | −1.71K | $16.53 | −$28.3K | −4.8%33.9K after | |
| May 23, 2024 (view filing) | May 21-23 | 2 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −32.4K | $12.23 | −$395.6K | −12.2%232.7K after | 2 lots |
| May 31, 2024 (view filing) | May 30-31 | 1 day | Kruse BoEVP, CFO, SECRY & TREAS. | SSale | −60.0K | $12.05 | −$723.1K | −22.2%210.9K after | 2 lots |
| Jun 11, 2024 (view filing) | Jun 10-11 | 1 day | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −70.0K | $12.02 | −$841.0K | −30.1%162.7K after | 2 lots |
| Jun 11, 2024 (view filing) | Jun 10 | 1 day | Ber GerardDirector | SSale | −722 | $12.00 | −$8.66K | −31.0%1.61K after | |
| Aug 27, 2024 (view filing) | Aug 26 | 1 day | Wilms JorisSVP & CHIEF OPERATING OFFICER | SSale | −5.00K | $14.69 | −$73.5K | −14.0%30.6K after | |
| Aug 30, 2024 (view filing) | Aug 28 | 2 days | Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICER | SSale | −50.0K | $15.37 | −$768.5K | −58.4%35.6K after | |
| Sep 17, 2024 (view filing) | Sep 13-16 | 4 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −95.0K | $13.31 | −$1.26M | −58.4%67.7K after | 2 lots |
| Mar 11, 2025 (view filing) | Mar 7 | 4 days | Gad ThomasCHIEF BUSINESS OFFICER | SSale | −10.8K | $5.23 | −$56.5K | −5.1%202.7K after | |
| Mar 11, 2025 (view filing) | Mar 7 | 4 days | Rossi Michael JPRESIDENT & CEO | SSale | −3.92K | $5.20 | −$20.4K | −2.8%137.1K after |